

CME CREDIT **EDUCATIONAL OBJECTIVE:** Readers will consider screening for and treating depression in their patients with heart disease

LEO POZUELO, MD

Section Head, Consultation Psychiatry, Department of Psychiatry and Psychology; Associate Director, Bakken Heart-Brain Institute; and Department of Cardiovascular Medicine, Cleveland Clinic

GEORGE TESAR, MD

Chairman, Department of Psychiatry and Psychology, Cleveland Clinic

JIANPING ZHANG, MD, PhD

Department of Psychiatry, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY

MARC PENN, MD, PhD

Director, Bakken Heart-Brain Institute; Director, Cardiac Intensive Care Unit; Department of Stem Cell Biology and Regenerative Medicine; and Department of Biomedical Engineering, Cleveland Clinic

KATHLEEN FRANCO, MD

Department of Psychiatry and Psychology, Cleveland Clinic; Associate Dean, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

WEI JIANG, MD

Associate Professor, Medicine, Psychiatry, and Behavioral Sciences, Duke University Medical Center, Durham, NC; Investigator, Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART)-CHF study

Depression and heart disease: What do we know, and where are we headed?

ABSTRACT

Depression and heart disease have an intricate association and perhaps a causal relationship. We review the current status of depression and heart disease and provide an algorithm for diagnosing and treating depression in cardiac patients that internists and cardiologists can use in their daily patient encounters.

KEY POINTS

Depression is a risk factor for new cardiac disease and has a detrimental impact in established cardiac disease.

Numerous mechanistic pathways have been implicated.

In clinical trials, drug therapy and psychotherapy have not clearly decreased the rate of cardiac death in depressed cardiac patients, but they did improve depression, adherence to drug therapy, and quality of life.

Clinicians should routinely screen for depression in cardiac patients and should not hesitate to treat it.

Eligible patients should routinely be referred to cardiac rehabilitation programs.

DEPRESSION IS A RISK FACTOR for heart disease, and in patients with heart disease, it is a risk factor for complications and death. Unfortunately, in the trials performed to date, treating depression in cardiac patients did not lead to lower rates of recurrent cardiovascular events or death. Nevertheless, we recommend that clinicians systematically screen for it in their heart patients, in view of the benefits of antidepressant therapy.

In this article we review key epidemiologic and psychosocial studies, the mechanistic links between depression and heart disease, and recent intervention trials. We also offer practical management advice and address the continued need for guidelines and risk stratification in the treatment of depressed cardiac patients.

After we submitted our review article, the American Heart Association (AHA)¹ released a consensus document recommending that health care providers screen for and treat depression in patients with coronary heart disease. We will discuss the same screening tests that have been recommended by the AHA.

DEPRESSION AND HEART DISEASE: COMMON AND LINKED

Depression and heart disease are very common and often coexist: the prevalence of depression in various heart conditions ranges from 15% to 20%.¹⁻³ According to data from the World Health Organization, by the year 2020 depression will be the second-leading cause of disability in developed countries (after heart disease).⁴

The World Health Survey⁵ showed that depression worsens health more than angina, arthritis, asthma, or diabetes. Furthermore, patients with severe mental illness have a higher risk of dying from heart disease and stroke.⁶

■ SOME HEART DISEASE RISK FACTORS ARE PSYCHOSOCIAL

In the 1980s, the “type A” personality (ambitious, aggressive, hostile, and competitive, with a chronic sense of urgency) was linked to heart disease.⁷ Later studies differed as to whether the entire set of features is valid as a collective risk factor for progressive heart disease,⁸ but hostility remains a validated risk factor and a focus of behavior modification.^{9,10}

Other psychosocial risk factors have been implicated,^{11,12} one of which is social isolation.^{9,13} Another is the “type D” personality, which includes a tendency to experience negative emotions across time and situations coupled with social inhibition and which is believed to be more valid than the type A personality as a risk factor for cardiac disease.^{14,15}

The INTERHEART study¹⁶ gathered data about attributable risk in the development of myocardial infarction (MI) in 52 countries in a case-control fashion. Psychosocial factors including stress, low generalized locus of control (ie, the perceived inability to control one's life), and depression accounted for 32.5% of the attributable risk for an MI.¹⁷ This would mean that they account for slightly less attributable risk than that of lifetime smoking but more than that of hypertension and obesity.

Job stress increases the risk of initial coronary heart disease¹⁸ and also the risk of recurrent cardiac events after a first MI.¹⁹ Even though numerous psychosocial risk factors have been associated with coronary heart disease, including anxiety,^{20,21} depression is perhaps the best studied.

■ PROSPECTIVE STUDIES OF DEPRESSION AND HEART DISEASE

To examine the impact of depression in coronary heart disease, prospective studies have been done in healthy people and in patients with established cardiovascular disease who develop depression.²²

In healthy people, depression increases the risk of coronary disease

The 1996 Epidemiologic Catchment Area study²³ found that people with major depression had a risk of MI four times higher than the norm, and people with 2 weeks of sadness or dysphoria had a risk two times higher.

A subsequent meta-analysis of 11 studies,²⁴ which included 36,000 patients, found that the overall relative risk of developing heart disease in depressed but healthy people was 1.64.

A meta-analysis by Van der Kooy et al²⁵ of 28 epidemiologic studies with nearly 80,000 patients showed depression to be an independent risk factor for cardiovascular disease.

Wulsin and Singal²⁶ performed a systematic review to see if depression increases the risk of coronary disease. In 10 studies with a follow-up of more than 4 years, the relative risk in people with depression was 1.64, which was less than that in active smokers (2.5) but more than that in passive smokers (1.25).

Depression can also exacerbate the classic risk factors for coronary disease, such as smoking, diabetes, obesity, and physical inactivity.²⁷

A 2007 study from Sweden²⁸ prospectively followed patients who were hospitalized for depression. The odds ratio of developing an acute MI was 2.9, and the risk persisted for decades after the initial hospitalization.

A prospective United Kingdom cohort study of people initially free of heart disease revealed major depression to be associated with a higher rate of death from ischemic heart disease.²⁹ Specifically, patients who had depression currently or in the past 12 months had a 2.7 times higher risk of dying than those who had never had depression or who had had it more than 12 months previously.

In existing heart disease, depression predicts recurrent events, death

Carney et al³⁰ found that patients with major depressive disorder had a higher incidence of new cardiac events in the 12 months after undergoing cardiac catheterization than those without major depressive disorder.

Frasere-Smith et al,³¹ in a landmark study, showed that patients who were depressed at 1 week after an MI were three to four times

Depression may be a stronger risk factor for MI than obesity, hypertension, or second-hand smoking

more likely to die in the next 6 months than nondepressed post-MI patients. Even after 18 months, depression remained an independent risk factor for cardiac-related death.³²

In longer studies (with up to 19.4 years of follow-up), depression was associated with higher rates of death from cardiac and all causes in patients with coronary artery disease.³³ Lespérance et al³⁴ found that in MI patients, the higher the Beck Depression Inventory score at the time of hospital admission, the higher the 5-year death rate.

Using meta-analysis, Barth et al³⁵ found the risk of dying in the first 2 years after initial assessment to be twice as high in depressed cardiac patients as in nondepressed cardiac patients (odds ratio 2.24).

Van Melle et al³⁶ reviewed 22 studies and found that in the 2 years after an MI, depressed patients had a 2 to 2.5 times higher risk of dying of a cardiac or any other cause than did nondepressed patients.

Depression also predicts higher morbidity and mortality rates in patients undergoing coronary artery bypass grafting,^{37,38} patients with congestive heart failure,³⁹ and heart transplant recipients.⁴⁰

MEDICAL ILLNESS CAN PREDISPOSE TO DEPRESSION, AND VICE VERSA

Medical illnesses can predispose a patient to develop depression. Specifically, compared with healthy people, cardiac patients appear to be at greater risk of developing depression for many years after the initial medical diagnosis is made.⁴¹

Katon et al⁴² reviewed 31 studies involving 16,922 patients, that assessed the impact of depression and anxiety in chronic medical illnesses such as heart disease, diabetes, pulmonary disease, and arthritis. After the severity of the medical disorder was controlled for, patients with depression and anxiety reported a higher number of medical symptoms.

DEPRESSION WORSENS QUALITY OF LIFE AND ADHERENCE TO TREATMENT

Depressed patients perceive their health status and quality of life negatively. In the Heart and Soul study,⁴³ depressive symptoms and low

exercise capacity—but not low ejection fraction or ischemia—were significantly associated with perceived deterioration of health in patients with coronary artery disease.

After an MI, patients who take their cardiac drugs properly have a better chance of survival.^{44,45} Clinical depression can worsen compliance with cardiac medication regimens,⁴⁶ and reducing depression increases medication adherence overall.⁴⁷ Not surprisingly, depressed patients also adhere less well to other recommendations,⁴⁸ including modifying the diet, exercising, stopping smoking, and attending cardiac rehabilitation programs.⁴⁹

PLAUSIBLE MECHANISMS LINK DEPRESSION AND HEART DISEASE

Traditional cardiac risk factors such as smoking, high cholesterol, hypertension, diabetes, and obesity tend to cluster in depressed patients.⁵⁰ Other mechanisms linking depression and heart disease are reviewed below.^{51,52}

Autonomic imbalance

Excessive sympathetic stimulation or diminished vagal stimulation or both are associated with higher rates of morbidity and death.⁵³

Lack of variability in the heart rate reflects a sympathetic-vagal imbalance and is a risk factor for ventricular arrhythmias and sudden cardiac death in patients with cardiovascular disease.⁵⁴ Carney et al⁵⁵ reported that patients with coronary artery disease and depression had significantly less heart rate variability than nondepressed cardiac patients. Similarly, after an MI, depressed patients had significantly less heart rate variability than nondepressed patients,⁵⁶ implying that low heart rate variability may mediate the adverse effect of depression on survival after an MI.⁵⁷

In the Heart and Soul study, Gehi et al⁵⁸ found no distinct relationship between heart rate variability and depression. However, in the same study, de Jong et al⁵⁹ did find specific somatic symptoms of depression to be associated with lower heart rate variability, although cognitive symptoms were not.

Platelet activation, endothelial dysfunction

Depressed patients have been found to have

After an MI, depressed patients are twice as likely to die as non-depressed patients

**The better that
MI patients
comply with
their medi-
cations, the
better their
survival**

exaggerated platelet reactivity.⁶⁰ Plasma levels of platelet factor IV and beta-thromboglobulin, markers of platelet activation, are higher in depressed patients with ischemic heart disease than in nondepressed patients with ischemic heart disease and in control patients.⁶¹ This activation of platelets can lead to vascular damage and thrombosis.

In a subset study of the Sertraline Anti-Depressant Heart Attack Randomized Trial (SADHART), depressed MI patients were treated with sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), and had substantially less platelet and endothelial biomarker release.⁶²

Depressed cardiac patients also have impaired flow-mediated dilation of the brachial artery, a sign of endothelial dysfunction.⁶³ Although a recent study did not find coronary endothelial dysfunction in depressed patients who did not have cardiac disease, these patients had more clustering of other cardiac risk factors.⁶⁴

Hypothalamic-pituitary-adrenocortical and sympathetic adrenal medullary activation

High cortisol levels can accelerate the development of hypertension and atherosclerosis and result in endothelial vascular injury. Sympathoadrenal activation in turn can lead to higher levels of catecholamines, predisposing to vasoconstriction, a rapid heart rate, and platelet activation. Depressed patients have more activation of the hypothalamic-pituitary-adrenocortical and sympathetic adrenal medullary systems,^{51,65} yet another plausible mechanism for worse clinical outcomes in depressed cardiac patients.

Sudden emotional stress can cause transient left ventricular dysfunction, even in people without coronary disease, an effect that may be mediated by elevated plasma catecholamine levels.⁶⁶

Inflammatory cytokines

Inflammatory cytokines play a key role in the development of atherosclerosis.⁶⁷ C-reactive protein, an acute-phase reactant produced in hepatocytes, can be induced by cytokines such as interleukin 6. Damage to endothelial tissues leads to the release of inflammatory cytokines, including interleukin 1, interleukin 6, and tu-

mor necrosis factor alpha.

Depressed patients have higher levels of these inflammatory markers.^{68,69} A prospective study reported direct correlations between depression scores and C-reactive protein levels in post-MI patients.⁷⁰ The Heart and Soul study, however, did not confirm that coronary patients have more inflammation if they have depression,⁷¹ indicating that the relationship is complex and is perhaps more evident in specific types of depression.⁷²

Anticholinergic inflammatory pathway

Tracey⁷³ proposed a theory that vagal tone inhibits the release of inflammatory cytokines. This has important implications for treatment, as exercise, biofeedback, and meditation can stimulate the vagus nerve and therefore have beneficial anti-inflammatory effects.⁷⁴

Polymorphism in the serotonin transport promoter region gene

Research is focusing on the serotonin transport promoter region gene (5-HTTLPR).⁷⁵ The gene exists in two forms, a long one and a less-effective short one that appears to predispose to depression.⁷⁶

Nakatani et al⁷⁷ showed that MI patients were more likely to become depressed and to have subsequent cardiac events if one or both of their alleles of this gene were short. Otte et al,⁷⁸ using Heart and Soul study data, found that patients with a short allele had a higher likelihood of depression, higher perceived levels of stress, and higher urinary norepinephrine secretion. However, the long allele genotype may be associated with a higher risk of developing an MI.⁷⁹

Our knowledge of the genetic interplay of depression and cardiovascular disease is still in its infancy, and further studies are needed to clarify these findings.

■ IN TRIALS, LESS DEPRESSION BUT NO EFFECT ON DEATHS, RECURRENT MI

Major behavioral and drug trials conducted in the last 15 years have focused on how to best treat depression in cardiac patients.⁸⁰⁻⁸⁵

The Montreal Heart Attack Readjustment Trial (MHART)⁸¹ used telephone calls and home nursing visits to explore and monitor psychologi-

TABLE 1

Screening tests for depression: The Patient Health Questionnaire (PHQ-9)

Over the last 2 weeks, how often have you been bothered by any of the following problems?

	NOT AT ALL	SEVERAL DAYS	MORE THAN HALF THE DAYS	NEARLY EVERY DAY
Little interest or pleasure in doing things	0	1	2	3
Feeling down, depressed, or hopeless	0	1	2	3
Trouble falling asleep or staying asleep, or sleeping too much	0	1	2	3
Feeling tired or having little energy	0	1	2	3
Poor appetite or overeating	0	1	2	3
Feeling bad about yourself—or that you are a failure or have let yourself or your family down	0	1	2	3
Trouble concentrating on things, such as reading the newspaper or watching television	0	1	2	3
Moving or speaking so slowly that other people could have noticed. Or the opposite—being so fidgety or restless that you have been moving around a lot more than usual	0	1	2	3
Thoughts that you would be better off dead, or thoughts of hurting yourself in some way	0	1	2	3
Add columns				
TOTAL*				

*A total score of 10 or higher indicates depression.

Two screening questions (PHQ-2)*

During the past month, have you often been bothered by being feeling down, depressed, or hopeless?
 During the past month, have you often been bothered by little interest or pleasure in doing things?

*An answer of yes to either question should be followed up with the PHQ-9, above.

PHQ-9 IS ADAPTED FROM PRIME MD TODAY, DEVELOPED BY DRS. ROBERT L. SPITZER, JANET B.W. WILLIAMS, KURT KROENKE, AND COLLEAGUES WITH AN EDUCATIONAL GRANT FROM PFIZER INC. FOR RESEARCH INFORMATION, CONTACT DR. SPITZER AT RIS8@COLUMBIA.EDU. USE OF THE PHQ-9 MAY ONLY BE MADE IN ACCORDANCE WITH THE TERMS OF USE AVAILABLE AT [HTTP://WWW.PFIZER.COM](http://www.pfizer.com).
 COPYRIGHT 1999 PFIZER INC. ALL RIGHTS RESERVED. PRIME MD TODAY IS A TRADEMARK OF PFIZER INC.

CAN BE DOWNLOADED AT WWW.PHQSCREENERS.COM

**Perhaps
talking about
one's stresses
in depth in the
post-MI period
is not helpful**

cal distress for up to 1 year after an MI. The overall trial did not show these interventions to have any impact on survival compared with usual care. In fact, in women receiving the telephone intervention, there was a trend toward higher rates of cardiac and all-cause death, which was quite unexpected. Uncovering stresses and problems without resolving them, rather than encouraging patients to place these on the “back burner,” may

partially explain these results.

SADHART⁸² studied the safety of sertraline in depressed post-MI patients. No major differences in cardiac function were noted between the sertraline and placebo groups, showing that sertraline was safe for these patients. The sertraline group had fewer cardiovascular events, but the difference was not statistically significant.

Cardiac patients may not realize they are depressed

The Enhancing Recovery in Coronary Heart Disease (ENRICH⁸³) study was primarily designed to see whether a psychosocial intervention would decrease deaths in depressed cardiac patients. Much to the chagrin of behavioral medicine, the group undergoing cognitive behavioral therapy did not have a higher rate of event-free survival, although the intervention had a favorable impact on depression and social support.

The Myocardial Infarction Depression Intervention Trial (MIND-IT)⁸⁴ looked at whether the antidepressant mirtazapine (Remeron) would improve long-term depression and cardiovascular outcomes in depressed post-MI patients. In 18 months of follow-up, neither objective was obtained.

The Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial⁸⁵ tested the efficacy of the SSRI citalopram (Celexa) and interpersonal therapy in a short-term intervention. Here, the antidepressant was superior to placebo in the primary outcome of treating depression, but interpersonal therapy had no advantage over “clinical management,” ie, a shorter, 20-minute supportive intervention.

Common threads in these studies.

- In ENRICH⁸³ and MIND-IT, patients whose depression did not respond to treatment were at higher risk of cardiac events during follow-up.^{86–88}
- In SADHART and CREATE, which used drug treatment, the antidepressant response was more robust in patients with a history of depression before their heart attacks, suggesting that a patient with recurrent depression at the time of a cardiac event should receive medication for it.^{85,89}

CLINICAL RECOMMENDATIONS

Use a depression screening tool

Ziegelstein et al⁹⁰ recently studied the ability of clinical personnel to detect depression in hospitalized MI patients. If a screening tool was not used, the results were abysmal, indicating the need to use formal screening for symptoms of depression in acute MI patients.

Many self-rating scales are available, among which are the Beck Depression Inventory (BDI) and the Hospital Anxiety and

Depression Scale (HADS). Others are:

The Patient Health Questionnaire (PHQ-9) is a nine-item tool, easy to administer and score (TABLE 1). It has been well studied in both screening for and follow-up of depression in primary care.^{91,92} It was used in the Heart and Soul study and the Prospective Registry Evaluating Outcomes After Myocardial Infarction: Events and Recovery (PREMIER) study.³ It has also been used to identify and document depressive symptoms in patients with acute coronary syndrome.⁹⁴ A cut-off score of 10 or higher on the PHQ-9 is diagnostic of depression.⁹⁵

The PHQ-2 consists of the two first questions of the PHQ-9, which deal with mood and lack of pleasure. A cut-off score of 3 or higher has a sensitivity of 83% and a specificity of 92%,⁹⁶ fulfilling the need for a quick and reliable depression screening tool. The clinician can also ask for a yes-or-no answer to the two questions of the PHQ-2 (TABLE 1). A yes to either of the two questions is up to 90% sensitive and 75% specific.^{92,97}

When to suspect depression in cardiac patients

Cardiac patients may not realize they have the classic symptoms of depression, since they often ascribe somatic symptoms to their heart disease and overlook emotional associations. Lespérance and colleagues⁹⁸ suggest that certain clues should make us suspect depression in cardiac patients (TABLE 2).

Which type of psychotherapy is best?

The negative results of psychosocial interventions (phone calls and home visits from a nurse) in MHART and of cognitive behavioral therapy in ENRICH⁸³ raise questions about which type of psychotherapy is best for depression in heart disease. CREATE found that 50-minute weekly sessions of interpersonal psychotherapy were no more beneficial than clinical management, ie, 20-minute weekly sessions that focused on compliance with treatment and education about depression and overall management. Perhaps a type of therapy akin to “clinical management” in this study or the brief behavior-based and targeted therapy used in the Improving Mood Promoting Access to Collaborative Care Treatment

(IMPACT) trials of depression in primary care⁹⁹ could be designed specifically to treat depression in cardiac disease. However, it is also quite possible that treatments that focus on uncovering stresses or problems may not be timely for these patients.

Which therapy is best for women is another area of consideration. In MHART, even after 5 years of follow-up,¹⁰⁰ women who received the psychosocial support intervention did marginally worse. In the ENRICHD study, women did not experience a benefit from cognitive behavioral therapy. Further studies must address sex differences in response to different therapies.

SSRIs seem to be better than other antidepressants for cardiac patients

Before SSRIs were available, tricyclic antidepressants were the mainstays. Subsequent analysis showed the tricyclics to have an unfavorable risk-benefit profile in cardiac patients,¹⁰¹ and since other types of antidepressants are available, tricyclics should be avoided altogether in cardiac patients.¹⁰²

Whether the SSRIs actually decrease one's risk of death in heart disease is still an issue of debate, but there are encouraging signs. In SADHART, the rate of death and recurrent nonfatal MI was 20% lower in the patients randomized to receive sertraline, although the difference was not statistically significant.⁸² In ENRICHD, patients who did not respond to cognitive behavioral treatment or had severe depression could receive sertraline or other antidepressant drugs on a nonrandomized basis, and those who did had a 42% lower incidence of death or recurrent MI.¹⁰³

The SADHART and CREATE trials provide convincing evidence of the cardiac safety and antidepressant efficacy of two SSRIs (sertraline and citalopram) in depressed cardiac patients. Mirtazapine, studied in MIND-IT, was not effective in treating depression in cardiac patients, although it had a better adverse effect and safety profile than tricyclic antidepressants.¹⁰⁴

Clinical observations indicate that SSRIs are associated with less risk of MI than non-SSRI drugs.^{105,106} During hospitalization for acute coronary syndromes, patients on SSRIs had lower rates of recurrent ischemia and heart

TABLE 2

Specific clues to depression in cardiac patients

Clinical symptoms and social functioning

Chronic fatigue
New irritability or anger
Feeling overwhelmed
Loss of weight without dieting
Sleep disturbance
Decreased social connection
Reduced interest in hobbies or pleasurable activities
Difficulty in coping with recent stress
Loss of confidence

Management problems

Low compliance with medications
Low compliance with lifestyle modification
Medical or emergency room visits for unexplained symptoms
Failure of reassurance in allaying anxiety or pessimism
Little or no progress in cardiac rehabilitation

ADAPTED FROM LESPÉRANCE F, FRASURE-SMITH N. DEPRESSION IN PATIENTS WITH CARDIAC DISEASE. J PSYCHOSOM RES 2000; 48:379–391.

failure but higher bleeding rates than patients not taking SSRIs.¹⁰⁷ In a retrospective study of patients undergoing coronary artery bypass grafting, those on an SSRI before surgery had higher rates of death and rehospitalization.¹⁰⁸ Being on antidepressant medication could be interpreted as a surrogate marker of having more severe depression before surgery; this issue clearly requires further study.

Given current observations and recent data from interventional trials coupled with the safe drug-interaction profile of sertraline and citalopram, these two SSRIs are recommended for treating depression in cardiac patients. If the patient is also receiving an anticoagulant, one should monitor for bleeding, as all SSRIs are associated with a prolonged bleeding time. Monitoring for rare cases of hyponatremia and bradycardia should also be part of early follow-up.

Do cardiac drugs have psychiatric effects?

Some concerns have arisen about cardiovascular drugs causing or aggravating psychiatric conditions.

All SSRIs interact with anticoagulants, prolonging the bleeding time

Interview patient

Preview specific considerations of depression in cardiac patients
Two-item questionnaire; if positive on one or both questions, follow with PHQ-9
A PHQ-9 score of 10 or higher suggests clinical depression

Discuss treatment of depression

Consider impact of depression on quality of life
Consider treatment if patient has ongoing or recurrent depression
Review treatment options

Pharmacotherapy

Selective serotonin reuptake inhibitors

Acute phase: 1–3 months
Sertraline (Zoloft) 20–150 mg target dose
Citalopram (Celexa) 10–40 mg target dose

Continuation phase: 4–9 months
Then, slowly taper off the medication

Brief psychotherapy

Three to six sessions
Cognitive behavioral therapy or clinical management

Monitoring of depression treatment

More frequently (every 2 weeks) first 4–6 weeks, afterwards as clinically warranted
Document progress with follow-up PHQ-9 and adjust treatment as necessary

Refer to cardiac rehabilitation, if eligible

The SMILE study:
Exercise was as effective as drug treatment for depression

FIGURE 2. Our algorithm for detecting and treating depression in cardiac patients.

Statins were once suspected of causing clinical depression or even suicide. However, subsequent studies have not substantiated this.^{109,110} In fact, long-term statin use has been associated with improved psychological well-being.¹¹¹ Whether the favorable psychological profile is due to an improved lifestyle, a direct noncholesterol effect, or an immunomodulatory effect has yet to be determined.

Beta-blockers have been suspected of increasing depression and fatigue. Robust meta-analyses have shown no increased risk of depressive symptoms but a small increased risk of fatigue and sexual dysfunction.¹¹² Observational trials in the first year post-MI have shown no differences between beta-blocker users and nonusers in depressive symptoms or depressive disorders.¹¹³

Statins and beta-blockers offer both im-

mense cardiac benefit and low risk, and both may be prescribed with confidence in depressed cardiac patients.

Refer patients for cardiac rehabilitation

The American Association of Cardiovascular and Pulmonary Rehabilitation strongly recommends screening cardiac patients for depression and referring them to cardiac rehabilitation programs.¹¹⁴ Typical programs run 12 weeks, affording an opportunity to further listen to and assess the patient and to promote general wellness via nutrition, stress management, and exercise.

These interventions by themselves can favorably affect depression. Blumenthal and colleagues,¹¹⁵ in the Standard Medical Intervention and Long-Term Exercise (SMILE) study, found that exercise was as effective as

drug treatment in reducing depression. In addition, stress management as a psychosocial treatment in cardiac rehabilitation can reduce death rates in cardiac patients.¹¹⁶

Unfortunately, many patients who are eligible for cardiac rehabilitation programs do not avail themselves of them.¹¹⁷

Our algorithm

In view of the data outlined in this review, we propose an algorithm for use in depressed cardiac patients (FIGURE 2), which is similar to the algorithm proposed by the AHA committee,¹ but which we developed independently.

FUTURE DIRECTIONS FOR RESEARCH

Can we predict the course of depression?

We need to identify better which patients will have a spontaneous remission of their depressive symptoms after a cardiac event, which patients will linger with depression, and which patients will best respond to treatment. Risk stratification, using the psychiatric history, symptoms and severity of depression, and genetic predisposition¹¹⁸ might allow improved targeted therapies.

Does depression cause cardiac disease?

The link between depression and heart disease can be seen as merely an association. In the interventional trials performed to date, we have not yet seen a reduction in cardiac deaths when depression was treated, challenging any assumption of a causal relationship between depression and heart disease. The debate about association vs cause is germane to behavioral medicine,¹¹⁹ and the better we understand the mechanistic pathways, the better we can advise patients and treat depression comorbid with heart disease.

Behavioral medicine is currently measuring the aspects of depression associated with cardiac disease, including the spectrum of somatic (body) and affective (mood) symptoms¹²⁰ and specific areas such as sympathetic arousal and early morning insomnia.¹²¹ If we can determine the depression subtype that carries a worse cardiac prognosis, we may untangle the biobehavioral links that bidirectionally bridge clinical depression and cardiac disease.

Another area of interest, emotional vital-

ity (a positive state associated with interest, enthusiasm, excitement, and energy for living) has been shown to protect against coronary heart disease¹²² and holds much promise.

In the plenary lecture of the Academy of Psychosomatic Medicine in 2006, Frasure-Smith spoke of the “pleiotropism” of our antidepressant interventions on the various risk factors in depressed cardiac patients.¹²³ We need behavioral medicine studies that elucidate these mechanisms, guiding more precise treatments as well as novel therapies. Omega-3 fatty acids, which benefit heart disease and clinical depression,¹²⁴ will be used in a randomized controlled trial by Lespérance and colleagues.¹²⁵ We await the results of this exciting research.

Will treating depression help in other types of heart disease?

The SADHART-CHF trial is examining whether 12 weeks of sertraline therapy is better than placebo in preventing death and improving cardiac outcomes in patients with chronic heart failure and comorbid major depressive disorder. It was to be completed in the fall of 2008. The results and experience of this study will help in designing future interventional trials to reduce the risk of depression in cardiovascular diseases.

We also await the results of a National Heart, Lung, and Blood Institute (NHLBI) trial, “Bypassing the Blues,” which is studying the treatment of depression after cardiac bypass surgery. This study should provide further insights into management of the depressed cardiac patient. Further prognostic studies in cardiac patients are also needed using the PHQ-9 and its shorter version, PHQ-2.

Current and future guidelines

For years our European colleagues have been ahead of us in recognizing depression screening and stress management as key to cardiac disease-prevention strategies.¹²⁶ The NHLBI nicely outlined recommendations on the assessment and treatment of depression in cardiovascular patients.¹²⁷ The just-published AHA Science Advisory should further encourage clinicians to screen and treat depression in the patient population.¹ As our knowledge grows, we look forward to future evidence-based guidelines for depressed cardiac patients. ■

Whether depression causes heart disease is up for debate

REFERENCES

- Lichtman JH, Bigger JT, Blumenthal JA, et al. Depression and coronary heart disease. Recommendations for screening, referral, and treatment. *Circulation* 2008; 118:1768–1775.
- Jiang W, Glassman A, Krishnan R, O'Connor CM, Califf RM. Depression and ischemic heart disease: what have we learned so far and what must we do in the future? *Am Heart J* 2005; 150:54–78.
- Freedland KE, Rich MW, Skala JA, Carney RM, Davila-Roman VG, Jaffe AS. Prevalence of depression in hospitalized patients with congestive heart failure. *Psychosom Med* 2003; 65:119–128.
- Murray CJ, Lopez AD, Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. *Lancet* 1997; 349:1436–1442.
- Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet* 2007; 370:851–858.
- Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database. *Arch Gen Psychiatry* 2007; 64:242–249.
- Friedman M, Thoresen CE, Gill JJ, et al. Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients: summary results of the recurrent coronary prevention project. *Am Heart J* 1986; 112:653–665.
- Ragland DR, Brand RJ. Type A behavior and mortality from coronary heart disease. *N Engl J Med* 1988; 318:65–69.
- Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. *Circulation* 1999; 99:2192–2217.
- Iribarren C, Sidney S, Bild DE, et al. Association of hostility with coronary artery calcification in young adults: the CARDIA study. *Coronary Artery Risk Development in Young Adults*. *JAMA* 2000; 283:2546–2551.
- Williams RB, Barefoot JC, Schneiderman N. Psychosocial risk factors for cardiovascular disease: more than one culprit at work. *JAMA* 2003; 290:2190–2192.
- Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. *J Am Coll Cardiol* 2005; 45:637–651.
- Hemingway H, Marmot M. Evidence based cardiology: psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies. *BMJ* 1999; 318:1460–1467.
- Denollet J. DS14: Standard assessment of negative affectivity, social inhibition, and type D personality. *Psychosom Med* 2005; 67:89–97.
- Steptoe A, Molloy GJ. Personality and heart disease. *Heart* 2007; 93:783–784.
- Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004; 364:937–952.
- Rosengren A, Hawken S, Ôunpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. *Lancet* 2004; 364:953–962.
- Kuper H, Marmot M. Job strain, job demands, decision latitude, and risk of coronary heart disease within the Whitehall II study. *J Epidemiol Community Health* 2003; 57:147–153.
- Aboa-Eboule C, Brisson C, Maunsell E, et al. Job strain and risk of acute recurrent coronary heart disease events. *JAMA* 2007; 298:1652–1660.
- Frasure-Smith N, Lespérance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. *Arch Gen Psychiatry* 2008; 65:62–71.
- Shen B-J, Avivi YE, Todaro JF, et al. Anxiety characteristics independently and prospectively predict myocardial infarction in men. *J Am Coll Cardiol* 2008; 51:113–119.
- Carney RM, Freedland KE. Depression, mortality, and medical morbidity in patients with coronary heart disease. *Biol Psychiatry* 2003; 54:241–247.
- Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. *Circulation* 1996; 94:3123–3129.
- Rugulies R. Depression as a predictor for coronary heart disease. A review and meta-analysis. *Am J Prev Med* 2002; 23:51–61.
- Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. *Int J Geriatr Psychiatry* 2007; 22:613–626.
- Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. *Psychosom Med* 2003; 65:201–210.
- Wulsin LR. Is depression a major risk factor for coronary disease? A systematic review of the epidemiologic evidence. *Harv Rev Psychiatry* 2004; 12:79–93.
- Janszky I, Ahlbom A, Hallqvist J, Ahnve S. Hospitalization for depression is associated with an increased risk for myocardial infarction not explained by lifestyle, lipids, coagulation, and inflammation: The SHEEP Study. *Biol Psychiatry* 2007; 62:25–32.
- Surtees PG, Wainwright NWJ, Luben RN, Wareham NJ, Bingham SA, Khaw K-T. Depression and ischemic heart disease mortality: evidence from the EPIC-Norfolk United Kingdom Prospective Cohort Study. *Am J Psychiatry* 2008; 165:515–523.
- Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. *Psychosom Med* 1988; 50:627–633.
- Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. *JAMA* 1993; 270:1819–1825.
- Frasure-Smith N, Lespérance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. *Circulation* 1995; 91:999–1005.
- Barefoot JC, Helms MJ, Mark DB, et al. Depression and long-term mortality risk in patients with coronary artery disease. *Am J Cardiol* 1996; 78:613–617.
- Lespérance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. *Circulation* 2002; 105:1049–1053.
- Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. *Psychosom Med* 2004; 66:802–813.
- van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. *Psychosom Med* 2004; 66:814–822.
- Blumenthal JA, Lett HS, Babyak MA, et al. Depression as a risk factor for mortality after coronary artery bypass surgery. *Lancet* 2003; 362:604–609.
- Sullivan MD, LaCroix AZ, Spertus JA, Hecht J, Russo J. Depression predicts revascularization procedures for 5 years after coronary angiography. *Psychosom Med* 2003; 65:229–236.
- Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. *Arch Intern Med* 2001; 161:1849–1856.
- Zipfel S, Schneider A, Wild B, et al. Effect of depressive symptoms on survival after heart transplantation. *Psychosom Med* 2002; 64:740–747.
- Polsky D, Doshi JA, Marcus S, et al. Long-term risk for depressive symptoms after a medical diagnosis. *Arch Intern Med* 2005; 165:1260–1266.
- Katon W, Lin EHB, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. *Gen Hosp Psychiatry* 2007; 29:147–155.
- Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life: the Heart

- and Soul Study. *JAMA* 2003; 290:215–221.
44. **Rasmussen JN, Chong A, Alter DA.** Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. *JAMA* 2007; 297:177–186.
 45. **Gehi AK, Ali S, Na B, Whooley MA.** Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. *Arch Intern Med* 2007; 167:1798–1803.
 46. **Gehi A, Haas D, Pipkin S, Whooley MA.** Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. *Arch Intern Med* 2005; 165:2508–2513.
 47. **Rieckmann N, Gerin W, Kronish IM, et al.** Course of depressive symptoms and medication adherence after acute coronary syndromes: an electronic medication monitoring study. *J Am Coll Cardiol* 2006; 48:2218–2222.
 48. **Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE.** Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. *Arch Intern Med* 2000; 160:1818–1823.
 49. **Kronish IM, Rieckmann N, Halm EA, et al.** Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. *J Gen Intern Med* 2006; 21:1178–1183.
 50. **Joynt KE, Whellan DJ, O'Connor CM.** Depression and cardiovascular disease: mechanisms of interaction. *Biol Psychiatry* 2003; 54:248–261.
 51. **Musselman DL, Evans DL, Nemeroff CB.** The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. *Arch Gen Psychiatry* 1998; 55:580–592.
 52. **Lespérance F, Frasure-Smith N.** Depression and heart disease. *Cleve Clin J Med* 2007; 74(suppl 1):S63–S66.
 53. **Curtis BM.** Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. *Mayo Clin Proc* 2002; 77:45–54.
 54. **Topol EJ.** *Textbook of Cardiovascular Medicine*, 2nd ed. Philadelphia: Lippincott Williams & Williams 2002.
 55. **Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS.** Association of depression with reduced heart rate variability in coronary artery disease. *Am J Cardiol* 1995; 76:562–564.
 56. **Carney RM, Blumenthal JA, Stein PK, et al.** Depression, heart rate variability, and acute myocardial infarction. *Circulation* 2001; 104:2024–2028.
 57. **Carney RM, Blumenthal JA, Freedland KE, et al.** Low heart rate variability and the effect of depression on post-myocardial infarction mortality. *Arch Intern Med* 2005; 165:1486–1491.
 58. **Gehi A, Mangano D, Pipkin S, Browner WS, Whooley MA.** Depression and heart rate variability in patients with stable coronary heart disease: findings from the Heart and Soul Study. *Arch Gen Psychiatry* 2005; 62:661–666.
 59. **de Jonge P, Mangano D, Whooley MA.** Differential association of cognitive and somatic depressive symptoms with heart rate variability in patients with stable coronary heart disease: findings from the Heart and Soul Study. *Psychosom Med* 2007; 69:735–739.
 60. **Musselman DL, Tomer A, Manatunga AK, et al.** Exaggerated platelet reactivity in major depression. *Am J Psychiatry* 1996; 153:1313–1317.
 61. **Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS.** Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. *Biol Psychiatry* 1997; 42:290–295.
 62. **Serebruany VL, Glassman AH, Malinin AI, et al.** Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. *Circulation* 2003; 108:939–944.
 63. **Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA.** Impaired endothelial function in coronary heart disease patients with depressive symptomatology. *J Am Coll Cardiol* 2005; 46:656–659.
 64. **Yang EH, Lerman S, Lennon RJ, Simari RD, Lerman LO, Lerman A.** Relation of depression to coronary endothelial function. *Am J Cardiol* 2007; 99:1134–1136.
 65. **Otte C, Neylan TC, Pipkin SS, Browner WS, Whooley MA.** Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. *Am J Psychiatry* 2005; 162:2139–2145.
 66. **Wittstein IS, Thiemann DR, Lima JAC, et al.** Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Engl J Med* 2005; 352:539–548.
 67. **Hansson GK.** Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; 352:1685–1695.
 68. **Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA.** Clinical depression and inflammatory risk markers for coronary heart disease. *Am J Cardiol* 2002; 90:1279–1283.
 69. **Empena JP, Sykes DH, Luc G, et al.** Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). *Circulation* 2005; 111:2299–2305.
 70. **Frasure-Smith N, Lespérance F, Irwin MR, Sauvé C, Lespérance J, Thérioux P.** Depression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes. *Biol Psychiatry* 2007; 62:302–308.
 71. **Whooley MA, Caska CM, Hendrickson BE, Rourke MA, Ho J, Ali S.** Depression and inflammation in patients with coronary heart disease: findings from the Heart and Soul Study. *Biol Psychiatry* 2007; 62:314–320.
 72. **Glassman AH, Miller GE.** Where there is depression, there is inflammation...sometimes! *Biol Psychiatry* 2007; 62:280–281.
 73. **Tracey KJ.** Physiology and immunology of the cholinergic antiinflammatory pathway. *J Clin Invest* 2007; 117:289–296.
 74. **Tracey KJ.** The inflammatory reflex. *Nature* 2002; 420:853–859.
 75. **McCaffery JM, Frasure-Smith N, Dubé M-P, et al.** Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. *Psychosom Med* 2006; 68:187–200.
 76. **Caspi A, Sugden K, Moffitt TE, et al.** Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. *Science* 2003; 301:386–389.
 77. **Nakatani D, Sato H, Sakata Y, et al.** Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. *Am Heart J* 2005; 150:652–658.
 78. **Otte C, McCaffery J, Ali S, Whooley MA.** Association of a serotonin transporter polymorphism (5-HTTLPR) with depression, perceived stress, and norepinephrine in patients with coronary disease: the Heart and Soul Study. *Am J Psychiatry* 2007; 164:1379–1384.
 79. **Fumeron F, Betoulle D, Nicaud V, et al.** Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Témoins de l'Infarctus du Myocarde (ECTIM). *Circulation* 2002; 105:2943–2945.
 80. **Rivelli S, Jiang W.** Depression and ischemic heart disease: what have we learned from clinical trials? *Curr Opin Cardiol* 2007; 22:286–291.
 81. **Frasure-Smith N, Lespérance F, Prince RH, et al.** Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. *Lancet* 1997; 350:473–479.
 82. **Glassman AH, O'Connor CM, Califf RM, et al.** Sertraline treatment of major depression in patients with acute MI or unstable angina. *JAMA* 2002; 288:701–709.
 83. **Writing Committee for the EI.** Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICH) randomized trial. *JAMA* 2003; 289:3106–3116.
 84. **van Melle JP, de Jonge P, Honig A, et al.** Effects of antidepressant treatment following myocardial infarction. *Br J Psychiatry* 2007; 190:460–466.
 85. **Lespérance F, Frasure-Smith N, Koszycki D, et al.** Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. *JAMA* 2007; 297:367–379.
 86. **Carney RM, Blumenthal JA, Freedland KE, et al.** Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICH) Study. *Psychosom Med* 2004; 66:466–474.

87. **de Jonge P, Honig A, van Melle JP, et al.** Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. *Am J Psychiatry* 2007; 164:1371–1378.
88. **Carney RM, Freedland KE.** Depression and coronary heart disease: more pieces of the puzzle. *Am J Psychiatry* 2007; 164:1307–1309.
89. **Glassman AH, Bigger JT, Gaffney M, Shapiro PA, Swenson JR.** Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. *Arch Gen Psychiatry* 2006; 63:283–288.
90. **Ziegelstein RC, Kim SY, Kao D, et al.** Can doctors and nurses recognize depression in patients hospitalized with an acute myocardial infarction in the absence of formal screening? *Psychosom Med* 2005; 67:393–397.
91. **Kroenke K, Spitzer RL, Williams JBW.** The PHQ-9. Validity of a brief depression severity measure. *J Gen Intern Med* 2001; 16:606–613.
92. **Löwe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K.** Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. *Med Care* 2004; 42:1194–1201.
93. **Parashar S, Rumsfeld JS, Spertus JA, et al.** Time course of depression and outcome of myocardial infarction. *Arch Intern Med* 2006; 166:2035–2043.
94. **Amin AA, Jones AMH, Nugent K, Rumsfeld JS, Spertus JA.** The prevalence of unrecognized depression in patients with acute coronary syndrome. *Am Heart J* 2006; 152:928–934.
95. **McManus D, Pipkin SS, Whooley MA.** Screening for depression in patients with coronary heart disease (data from the Heart and Soul Study). *Am J Cardiol* 2005; 96:1076–1081.
96. **Kroenke K, Spitzer RL, Williams JB.** The Patient Health Questionnaire-2: validity of a two-item depression screener. *Med Care* 2003; 41:1284–1292.
97. **Spitzer RL, Williams JB, Kroenke K, et al.** Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. *JAMA* 1994; 272:1749–1756.
98. **Lespérance F, Frasare-Smith N.** Depression in patients with cardiac disease. *J Psychosom Res* 2000; 48:379–391.
99. **Hunkeler EM, Katon W, Tang L, et al.** Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. *BMJ* 2006; 332:259–263.
100. **Frasare-Smith N, Lespérance F, Gravel G, Masson A, Juneau M, Bourassa MG.** Long-term survival differences among low-anxious, high-anxious and repressive copers enrolled in the Montreal Heart Attack Readjustment Trial. *Psychosom Med* 2002; 64:571–579.
101. **Glassman AH, Roose SP, Bigger JT Jr.** The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. *JAMA* 1993; 269:2673–2675.
102. **Cohen HW, Gibson G, Alderman MH.** Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. *Am J Med* 2000; 108:2–8.
103. **Taylor CB, Youngblood ME, Catellier D, et al.** Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. *Arch Gen Psychiatry* 2005; 62:792–798.
104. **Montgomery SA.** Safety of mirtazapine: a review. *Int Clin Psychopharmacol* 1995; 10(suppl 4):37–45.
105. **Sauer WH, Berlin JA, Kimmel SE.** Selective serotonin reuptake inhibitors and myocardial infarction. *Circulation* 2001; 104:1894–1898.
106. **Sauer WH, Berlin JA, Kimmel SE.** Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. *Circulation* 2003; 108:32–36.
107. **Ziegelstein RC, Meuchel J, Kim TJ, et al.** Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. *Am J Med* 2007; 120:525–530.
108. **Xiong GL, Jiang W, Clare R, et al.** Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. *Am J Cardiol* 2006; 98:42–47.
109. **Yang C-C, Jick SS, Jick H.** Lipid-lowering drugs and the risk of depression and suicidal behavior. *Arch Intern Med* 2003; 163:1926–1932.
110. **Callreus T, Agerskov Andersen U, Hallas J, Andersen M.** Cardiovascular drugs and the risk of suicide: a nested case-control study. *Eur J Clin Pharmacol* 2007; 63:591–596.
111. **Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM.** Long-term statin use and psychological well-being. *J Am Coll Cardiol* 2003; 42:690–697.
112. **Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM.** Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. *JAMA* 2002; 288:351–357.
113. **van Melle JP, Verbeek D, van den Berg MP, Ormel J, van der Line MR, de Jonge P.** Beta-blockers and depression after myocardial infarction. *J Am Coll Cardiol* 2006; 48:2209–2214.
114. **Thomas RJ, King M, Lui K, et al.** AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services. *J Am Coll Cardiol* 2007; 50:1400–1433.
115. **Blumenthal JA, Babyak MA, Doraiswamy PM, et al.** Exercise and pharmacotherapy in the treatment of major depressive disorder. *Psychosom Med* 2007; 69:587–596.
116. **Linden W, Phillips MJ, Leclerc J.** Psychological treatment of cardiac patients: a meta-analysis. *Eur Heart J* 2007; 28:2972–2984.
117. **Centers for Disease Control and Prevention.** Receipt of outpatient cardiac rehabilitation among heart attack survivors—United States, 2005. *JAMA* 2008; 299:1534–1536.
118. **Williams RB.** Treating depression after myocardial infarction: can selecting patients on the basis of genetic susceptibility improve psychiatric and medical outcomes? *Am Heart J* 2005; 150:617–619.
119. **Schneiderman N, Williams RB.** The great debate editorial, revisited. *Psychosom Med* 2006; 68:636–638.
120. **de Jonge P, Ormel J, van den Brink RHS, et al.** Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. *Am J Psychiatry* 2006; 163:138–144.
121. **Fraguas R, Jr, Iosifescu DV, Alpert J, et al.** Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D Study. *Psychosomatics* 2007; 48:418–425.
122. **Kubzansky LD, Thurston RC.** Emotional vitality and incident coronary heart disease: benefits of healthy psychological functioning. *Arch Gen Psychiatry* 2007; 64:1393–1401.
123. **Frasare-Smith N.** Reflections on depression as a cardiac risk factor. *Academy of Psychosomatic Medicine, 53rd Annual Meeting, Tucson, Arizona, 2006.*
124. **Frasare-Smith N, Lespérance F.** Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. *Biol Psychiatry* 2004; 55:891–896.
125. **Lespérance F.** Annual Research Award Lecture Academy of Psychosomatic Medicine, Amelia Island, Florida, 2007.
126. **Graham I, Atar D, Borch-Johnsen K, et al.** European guidelines on cardiovascular disease prevention in clinical practice: executive summary. *Eur Heart J* 2007; 28:2375–2414.
127. **Davidson KW, Kupfer DJ, Bigger JT, et al.** Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. *Psychosom Med* 2006; 68:645–650.

ADDRESS: Leopoldo Pozuelo, MD, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail pozuelo@ccf.org.